The FDA's New Registration Rule and What It Means for the Cigar World
The battle between America's premium cigar industry and the U.S. Food and Drug Administration has never really ended — it has simply evolved, round by round, into new arenas. The latest flashpoint arrived this summer when the FDA released a sweeping proposed rule titled Establishment Registration and Product Listing for Tobacco Products, a regulatory framework that, on its surface, sounds like routine administrative housekeeping. The Premium Cigar Association sees it as anything but. The PCA has stated it will submit formal comments opposing key portions of the rule, arguing the measure could impose significant compliance costs on manufacturers and retailers throughout the supply chain.
The stakes are real, the history is long, and the implications for every man who keeps a humidor at home — or simply enjoys a handmade cigar on a Friday evening — deserve a thorough accounting.
A Decade of Trench Warfare: The Road to This Moment
To understand why the PCA is sounding the alarm, it is necessary to understand what the premium cigar industry has already survived. In 2016, the FDA issued its final Deeming Rule, which extended the agency's tobacco regulatory authority to cover cigars, pipe tobacco, hookah, and several other products that had not previously been within the FDA's regulatory scope. For premium cigars specifically, this would have meant mandatory graphic health warnings on packaging similar to cigarette warning labels, premarket approval requirements — a multi-million-dollar process per SKU before a cigar could be legally sold — substantial equivalence reviews for established product lines, and user fees assessed against manufacturers and importers.
The industry did not accept this quietly. Premium cigar advocates, represented by the Cigar Rights of America and the Premium Cigar Association, argued from the start that premium cigars are a fundamentally different product than cigarettes and that the FDA had not done the rulemaking analysis required to apply the same regulatory regime to both. That argument, pressed through years of litigation at enormous cost to independent cigarmakers and their trade groups, ultimately prevailed.
Following a decade-long dispute between the premium cigar industry and the U.S. Food and Drug Administration, Judge Amit P. Mehta reaffirmed his 2023 decision that the FDA Deeming Rule will not apply to premium cigars as defined by the court. The district court's reasoning was substantive, not procedural. The court noted that the FDA failed to consider data submitted during the rulemaking process about usage patterns and attendant health risks, and that the FDA had obscured data regarding youth usage that showed only a miniscule percentage — 0.1 percent — of those who had reported smoking a cigar in the last 30 days had identified a premium cigar as their preferred brand.
The FDA appealed. The appellate court agreed with the lower court's core finding. The D.C. Circuit issued an opinion agreeing with the district court's ruling that the FDA acted arbitrarily and capriciously when it sought to include premium cigars in its Deeming Rule, and it affirmed the vacatur of the Deeming Rule as applied to premium cigars. Then, in April 2026, Judge Mehta issued yet another reaffirmation. Following the decade-long dispute, Judge Mehta reaffirmed his 2023 decision that the FDA Deeming Rule will not apply to premium cigars as defined by the court, and he once again ordered the Deeming Rule to be vacated, meaning that premium cigars are exempt from FDA regulation.
Drew Newman, the fourth-generation owner of J.C. Newman Cigar Co. — one of the oldest family-owned cigar companies in the United States — captured the emotional weight of that moment plainly. "For more than a decade, the premium cigar industry has been living in purgatory while we challenged FDA's decision to regulate premium cigars like cigarettes," Newman said. PCA CEO Joshua Habursky echoed the sentiment: "After nearly a decade of litigation, this decision provides clarity for retailers, manufacturers and consumers who have had to operate under significant regulatory uncertainty. Premium cigars clearly represent a distinct product category, and this outcome reflects the importance of considering those differences in any regulatory framework."
The New Proposed Rule: What the FDA Is Actually Asking For
Against that backdrop of hard-won legal victories, the FDA's latest proposed rule arrives with the industry's guard already up. The rule on Establishment Registration and Product Listing for Tobacco Products would require tobacco manufacturers — domestic and foreign alike — to formally register their operations with the federal government and submit detailed product listings. The FDA has framed this partly as a parity measure. The FDA describes the rule as a way to increase parity between domestic and foreign factories, noting that domestic factories are currently subject to additional requirements such as FDA inspections and more rigorous product listings, and that the proposed rule would extend these requirements to foreign factories and suppliers, leveling the playing field while also improving the FDA's tobacco regulatory mission.
"All companies selling tobacco products in the United States should play by the same rules," said Bret Koplow, acting director of the FDA's Center for Tobacco Products. The agency has also openly described the rule as targeting the illicit e-cigarette and vaping market. The proposal is described as a way to help combat the sales of illegal e-cigarettes and vaping products, a cause that has the support of both anti-tobacco groups and major tobacco companies alike.
The information demands under the proposed rule are detailed. The FDA has given examples of the types of information companies would need to provide, including the types of tobacco used, the size of the cigar, the type of packaging used, and what kind of characterizing flavor or flavors a product has — with specific examples even for tobacco growers or suppliers of cigar tobacco filler.
In terms of administrative burden, the agency estimates that up to 75 tobacco establishments will each submit one initial product list and material file information spreadsheet each year using the new Form FDA 3741b, which is expected to take two hours per submission. The FDA also estimates that confirmation or updating of establishment registration and product listing information will take 20 minutes annually per establishment. Those numbers may look modest in isolation, but the PCA's concern runs much deeper than paperwork hours.
Who Is Protected — and Who Is Not
Here is where the story gets genuinely complicated for the cigar industry. The hard-fought legal victories of the past decade do provide meaningful insulation for the most traditional, handmade premium products. The PCA acknowledges the release of the proposed rule and will provide comment before the September 14, 2026, deadline, noting that as a result of the premium cigar industry's successful litigation against the FDA's Deeming Rule, this proposed regulation will not apply to establishments that manufacture only "premium cigars" as defined by the court.
That legal definition is precise and non-negotiable. For purposes of its ruling, the court specified that premium cigars are those that are wrapped in whole tobacco leaf, contain a 100 percent leaf tobacco binder, contain at least 50 percent of the filler by weight in long filler tobacco, are handmade or hand rolled with no machinery beyond simple tools, have no filter or non-tobacco tip or mouthpiece, do not have a characterizing flavor other than tobacco, contain only tobacco, water, and vegetable gum with no other ingredients or additives, and weigh more than six pounds per 1,000 units. It is a strict eight-part test, and a product must satisfy every element to qualify.
The problem — and the PCA's central concern — is that this protection extends only so far. The association warned that many other products sold by its 3,500 retail members, including pipe tobacco and non-premium cigars, would be subject to new registration, recordkeeping, and inspection requirements under the proposed rule. The specifics are spelled out clearly in the PCA's statement. Foreign pipe tobacco, pipe manufacturers, and cigar manufacturers of products not meeting the eight-part "premium cigar" definition would be subject to new registration, listing, recordkeeping, and foreign factory inspection requirements if the rule is finalized.
One aspect of the rule represents a particularly sharp regulatory pivot. Mixed-use factories that produce both premium and non-premium cigars would be subject to this new regulation, effectively shifting the regulatory target from product type to producer. That is a meaningful structural change. A Nicaraguan or Dominican factory that rolls some blends qualifying as premium and others that do not — say, because one line uses a flavored binder — would no longer enjoy blanket protection. The entire operation would fall under the rule's requirements, regardless of how much of its output qualifies for the court-defined exemption.
The PCA Responds: Overregulation by Installment
The PCA's objections to this proposed rule are not born in a vacuum. In 2023, the PCA objected to a proposed rule on Requirements for Tobacco Products Manufacturing Practices, and the current Establishment Registration and Product Listing proposed rule contains provisions that, like that 2023 proposal, would have burdensome impacts on small businesses. The association sees a clear pattern — registration and compliance requirements that incrementally expand until they become crushing obligations for independent operators who cannot absorb regulatory overhead the way multinational tobacco conglomerates can.
PCA CEO Joshua Habursky made the association's position explicit and chose language that should resonate with anyone skeptical of regulatory capture: "Registration and inspection are usually the opening salvo of more regulations to come. When Big Tobacco and Anti-Tobacco Groups alike are celebrating an FDA proposed rule, you know there is a big problem for the overall marketplace." That observation cuts to the heart of a dynamic that plays out repeatedly in heavily regulated industries — that large incumbents and their ideological opponents can find common cause in rules that raise barriers to entry and squeeze out independent competitors, even when their motivations are entirely different.
The association did not stop at policy objections. It drew a straight economic line from manufacturer compliance costs to the consumer at the counter. The PCA stated it will oppose any regulation or provisions that increase costs on the products its members sell, especially when those costs are passed directly to retailers and their customers, noting that the vast majority of PCA member stores sell products that would be affected by this proposal and that higher compliance costs for manufacturers do not stay with manufacturers.
PCA CEO Joshua Habursky said the organization is concerned the proposal could lead to additional regulation and higher costs throughout the supply chain, particularly for small businesses. That concern has precedent. When the Deeming Rule was fully in force, estimates suggested that PMTA compliance costs would have raised wholesale costs on premium lines by as much as 30 to 50 percent per stick — a price increase that would have fundamentally altered who can afford to enjoy a fine handmade cigar in America.
The Broader Industry Landscape: Not Just Cigars
While the cigar world commands the most dramatic chapter of this ongoing regulatory saga, the proposed rule has implications that ripple well beyond the walk-in humidor. Pipe tobacco manufacturers and their global supply chains face new registration and foreign factory inspection requirements under the proposal. The tobaccos that fill a briar pipe — many of them blended, aged, and imported from specialty producers in England, Denmark, or the American South — would be drawn into a compliance web that currently exists primarily for cigarette manufacturers.
The foreign factory inspection component deserves particular attention. The prospect of FDA inspectors visiting cigar factories overseas is not a new one — in 2023, the agency announced a different proposed rule that would have gone multiple steps further, introducing not only inspections but also a variety of health and safety standards for manufacturing operations, including requirements for operating procedures covering safety and hygiene, as well as more extensive record-keeping. That earlier, more aggressive proposal never materialized. The 2026 proposal is nowhere near as strict, though it would still represent the monumental step of the FDA establishing foreign factory inspections, with the FDA highlighting many of the same benefits of the 2023 proposal while making parity a much more prominent talking point.
The Cigar Association of America, a separate trade organization that includes both machine-made cigar producers and handmade manufacturers, has taken a different posture toward the registration rule. In a June meeting with the government regarding the proposal, the CAA advocated for streamlined regulations, especially around private label cigars, but said the organization was supportive of the move. That divergence from the PCA's harder line is itself telling — the two organizations have not always been aligned, as demonstrated when the CAA attempted to broaden the legal definition of "premium cigar" to include flavored and machine-finished products, a move the PCA and Cigar Rights of America both opposed.
Defining Premium: The Line That Everything Turns On
The eight-part legal definition of "premium cigar" is not merely an academic exercise — it is the fault line that determines which products enjoy regulatory shelter and which do not. Judge Mehta reaffirmed the established definition, rejecting the Cigar Association of America's motion to modify and broaden it by trying to classify flavored cigars and cigars made by machine but finished by hand as premium. Flavored and machine-made cigars are not exempt from FDA oversight.
For the consumer, this has practical consequences. The flavored cigar lines that stock the back walls of many tobacconists — those aromatic, infused sticks that have built genuine cult followings — fall outside the court's definition and remain subject to federal regulation. Flavored and infused cigars have characterizing flavors beyond tobacco, and for retailers carrying flavored or machine-made products as part of their mix, those specific SKUs remain subject to FDA oversight. The proposed registration rule, if finalized, would add another layer of compliance burden to that portion of a shop's inventory.
The definition question also matters intensely for manufacturers in tobacco-growing regions throughout Central America, where many factories produce both premium and non-premium lines under the same roof to serve different market segments. Under the logic of the proposed rule, the existence of any non-qualifying product in a factory's output would expose the entire operation to registration and inspection requirements. That is a significant operational and financial consideration for family-owned producers operating in Nicaragua, Honduras, or the Dominican Republic — many of whom have been the very artisans whose craftsmanship the premium cigar exemption was designed to protect.
What Regulatory History Tells Us About What Comes Next
The PCA's warning that registration and inspection are the opening salvo of more regulations is grounded in how federal agency rulemaking actually works. An establishment registration requirement creates a database. A product listing requirement creates a detailed inventory of what exists in the market. Foreign factory inspections create enforcement infrastructure. Each of these, individually, may appear modest. Together, they constitute the scaffolding upon which more substantive regulatory requirements — ingredient restrictions, manufacturing practice mandates, premarket review triggers — can be constructed.
That is precisely why the PCA committed to filing formal comments before the September 14, 2026, deadline. The comment period is not a formality to the industry — it is a strategic battleground. The D.C. Circuit's earlier decision underscored the importance of thorough and evidence-based rulemaking by federal agencies, as well as the importance of interested stakeholders providing detailed public comments on proposed agency rules, with the ruling highlighting the need for the FDA to consider all relevant data and respond to empirical evidence when promulgating new regulations. In short, the same detailed public comment record that helped the industry win in court before will be the foundation of its next line of defense.
The PCA's comment strategy will almost certainly challenge the rule on small-business impact grounds, echoing its 2023 objections. The Establishment Registration and Product Listing for Tobacco Products proposed rule contains provisions that, like the 2023 proposed rule, would have burdensome impacts on small businesses. Regulatory burden analysis requirements under federal law — specifically the Regulatory Flexibility Act — obligate agencies to consider and minimize unnecessary compliance costs for small entities. Whether the FDA has done that analysis rigorously enough will likely be a central point of contention in the comments the PCA files.
The Gentleman's Perspective: What This Means at the Retail Level
For the man who frequents his local tobacconist — who knows the owner by name, who buys a box of Nicaraguan puros every few months, and who keeps a small collection of aged pipe tobaccos he found at a specialty shop — the immediate question is what, if anything, changes at the counter. In the near term, the answer for true premium cigars is: not much, provided the industry's legal victories hold. Cigarmakers won't have to put warning labels on cigar packaging or deal with other costly regulations proposed by the FDA's Deeming Rule, at least not for now.
But the broader ecosystem of a well-stocked tobacconist is more vulnerable. A shop that carries flavored cigars, pipe tobacco, and non-premium machine-made cigars alongside its handmade premium inventory is already navigating a split regulatory landscape. If the proposed registration rule is finalized as written, the supply chain for those non-exempt products gets more expensive and more complex — and those costs, as the PCA notes, do not stay with manufacturers. They travel downstream. Retailers absorb them or pass them along, and in a specialty category with relatively thin margins and a loyal but not enormous consumer base, either outcome has consequences.
The risk of regulatory attrition also bears watching. Every compliance burden — even a modest one — raises the cost of operating a small, independent tobacconist versus a large chain retailer or a direct-to-consumer online operation with dedicated compliance staff. Over time, that arithmetic favors consolidation and works against the kind of independent neighborhood cigar shop that is itself part of the premium cigar experience for most American aficionados.
The Comment Deadline and What Happens After
The PCA will provide formal comment on behalf of its membership before the September 14, 2026, deadline. That comment, along with responses from other industry stakeholders, public health organizations, and individual businesses, will become part of the official rulemaking record. The FDA is required to respond to significant comments and to justify its final rule in light of that record. Given the judiciary's demonstrated willingness to scrutinize whether the FDA actually engages with contrary evidence — as it found the agency had failed to do with premium cigar usage data during the Deeming Rule proceedings — a well-documented comment record has real legal value.
Whether the FDA ultimately finalizes the rule in its current form, modifies it in response to industry objections, or shelves it entirely will depend on a mix of legal, political, and administrative factors. The current regulatory environment has shifted considerably since the height of the Deeming Rule battles, and the FDA's appetite for expensive litigation over tobacco policy has been tested repeatedly. Industry observers note that at any time the FDA could decide to start the process of trying to regulate premium cigars again, and that retailers and operators should treat the current window as one of regulatory stability rather than a permanently settled policy outcome.
The PCA's posture is consistent, experienced, and clear. It has won this fight before by being organized, methodical, and willing to go the distance — in the courts, in the comment record, and on Capitol Hill. The PCA and allied organizations fought and won on behalf of premium cigars, retailers, manufacturers, and consumers, and that victory matters: this new proposed regulation would have hit every single premium cigar manufacturer if not for that important litigation, which provided clarity that premium cigars are a distinct product category.
The cigar is not a cigarette. A hand-rolled, long-filler, all-tobacco puro from a fourth-generation blender in Estelí is not a mass-produced nicotine delivery device. The courts have confirmed that distinction, and the PCA intends to make sure the FDA's next move does not quietly erode what a decade of litigation established. The comment period closes September 14, 2026, and every voice in the premium tobacco industry — manufacturer, retailer, and consumer — has a role to play in what comes next.
